💡 Quick answer
The landmark clinical studies, treatment history and latest research for Dutasteride — fact-checked and sourced.
Research & evidence
How treatment evolved
2002FDA approves oral dutasteride (Avodart, 0.5 mg) — a dual type I/II 5-alpha-reductase inhibitor — for benign prostatic hyperplasia, establishing the molecule and safety profile later repurposed off-label for hair loss.
2006Olsen et al. publish the first major randomized placebo-controlled dose-ranging trial of dutasteride vs finasteride for male pattern hair loss in JAAD, demonstrating dose-dependent hair regrowth and superiority of higher-dose dutasteride to finasteride.
2009South Korea becomes the first country to approve oral dutasteride 0.5 mg/day specifically for male androgenetic alopecia (the indication remains off-label in the US/EU).
2015Japan's PMDA approves dutasteride 0.5 mg (Zagallo) for male androgenetic alopecia, the second national regulatory approval for this indication (Deliberation Results, Sept 2015).
2014Gubelin Harcha et al. publish the large pivotal phase IIb/III RCT (917 men) in JAAD confirming dutasteride 0.5 mg significantly outperforms finasteride 1 mg on 24-week hair count, supporting the approvals.
Key clinical studies
Olsen et al., 20062006
Randomized, double-blind, placebo-controlled dose-ranging RCT; 416 men aged 21-45, 24 weeks
Dutasteride increased target-area hair count vs placebo in a dose-dependent manner; dutasteride 2.5 mg/day was superior to finasteride 5 mg/day at weeks 12 and 24, establishing that dual 5-alpha-reductase inhibition (lowering both scalp and serum DHT more completely) yields greater regrowth.
J Am Acad Dermatol (JAAD)
Gubelin Harcha et al., 20142014
Randomized, active- and placebo-controlled phase IIb/III RCT; 917 men aged 20-50, 24 weeks
Men received dutasteride 0.02/0.1/0.5 mg, finasteride 1 mg, or placebo daily. Hair count increased with dutasteride dose-dependently; dutasteride 0.5 mg significantly improved hair count, hair width and hair-growth assessment vs finasteride 1 mg at week 24 (reported P values ~.002-.004). This is the largest head-to-head trial and the basis for the Asian approvals.
Eun et al., 20102010
153 Korean men aged 18-49, randomized to oral dutasteride 0.5 mg/day vs placebo for 6 months (phase III, double-blind, placebo-controlled)
Oral dutasteride 0.5 mg/day significantly increased hair counts vs placebo over 6 months (+12.2/cm2 vs +4.7/cm2, P=.0319), with improved subject and investigator/panel photographic assessments. Note: this was an oral trial (not mesotherapy) and was placebo-controlled (no in-trial finasteride comparator).
J Am Acad Dermatol (JAAD)
Herz-Ruelas et al., 20202020
Systematic review of 8 studies (5 oral, 3 intralesional/mesotherapy dutasteride)
Both oral and intralesional (mesotherapy) dutasteride improved hair count, but evidence for the injectable route was weak: mean hair-count increase was larger for oral (MD ~15.9 hairs) than intralesional (MD ~7.9 hairs in a single study). Authors concluded data were insufficient for reliable route comparison — intralesional dutasteride remains experimental with low-quality, heterogeneous evidence.
Skin Appendage Disord (PMID 33313048)
Latest research: Recent work (2023-2026) focuses on alternative routes and dosing to keep dutasteride's potency while limiting systemic DHT suppression — including intralesional/mesotherapy dutasteride (a 2025 Journal of Cosmetic Dermatology systematic review/meta-analysis showed promising local hair-count gains but flagged small samples and high heterogeneity), low-dose 0.2 mg phase III trials, and intermittent (twice/thrice-weekly) oral regimens versus daily finasteride. A 2025 Bayesian network meta-analysis of ~33 RCTs also ranked oral dutasteride 0.5 mg/day as the most effective monotherapy for male AGA by 24-week hair density (highest SUCRA).
Summaries reflect published, peer-reviewed research and are not medical advice. See the linked sources for details.
Explore more
Self-check →Treatments →Transplant →Women →New →Hair Loss Causes →Hair-Loss Glossary →Hair-Loss Questions & Answers →Hair-Loss Ingredient Evidence Ratings →Hair Transplant Cost by City →Research →Browse all →
Not medical advice. General education only; it does not replace diagnosis or treatment by a licensed professional. Consult a board-certified dermatologist before starting, stopping or changing any treatment.
⚠️ When to see a doctor — don’t self-treat
- Sudden patchy or circular bald spots
- Redness, scaling, pus, pain or itch (possible scarring alopecia — treat urgently)
- Broken hairs or rapid loss
- Loss with body-wide signs (weight loss, fatigue, cycle changes, acne, extra hair)
- Loss right after a new medication
- Any hair loss in a child